Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.
News|Articles|February 15, 2008
Drug price comparison sites found ineffective
State-run drug price comparison sites hampered by missing data, according to a study by Center for Studying Health System Change.
Advertisement
Web sites run by 10 states that offer drug price comparisons offer limited data on prices and are not useful for most consumers, according to a report issued by the
Advertisement
Related to this article
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Study Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speech
3
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5